Adalimumab-induced lichenoid drug eruption
LMJ-Lebanese Medical Journal. 2014; 62 (4): 238-240
em Inglês
| IMEMR
| ID: emr-153677
ABSTRACT
Tumor necrosis factor [TNF]- alpha inhibitors are being widely and increasingly used for the management of a spectrum of rheumatologic diseases that are refractory to conventional disease modifying anti-rheumatic drugs. Various cutaneous side effects have been reported after treatment with TNF- alpha inhibitors. We present a case report of a 26-year- old male patient who developed a lichenoid drug eruption few months after the initiation of adalimumab for the manage- ment of Crohn's disease. We also highlight the clinical and histopathologic differences between lichenoid drug eruptions and idiopathic lichen planus
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Doença de Crohn
/
Fator de Necrose Tumoral alfa
/
Toxidermias
/
Anticorpos Monoclonais Humanizados
Tipo de estudo:
Relato de Casos
Limite:
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Lebanese Med. J.
Ano de publicação:
2014
Similares
MEDLINE
...
LILACS
LIS